Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PMB
|
|||
| Former ID |
DIB006278
|
|||
| Drug Name |
Imeglimin
|
|||
| Synonyms |
775351-65-0; UNII-UU226QGU97; UU226QGU97; Imeglimin [INN]; Emd 387008 (R-imeglimin) HCl; SCHEMBL2158106; SCHEMBL14868241; C6H13N5; DTXSID50228237; BCP11085; ZINC34380900; 3733AH; AKOS027338676; DB12509; CS-1751; HY-14771
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Phase 2 | [1] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [2], [3] | ||
| Company |
Merck KGaA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H13N5
|
|||
| Canonical SMILES |
CC1N=C(NC(=N1)N(C)C)N
|
|||
| InChI |
1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
|
|||
| InChIKey |
GFICWFZTBXUVIG-SCSAIBSYSA-N
|
|||
| CAS Number |
CAS 775351-65-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542) | |||
| REF 2 | ClinicalTrials.gov (NCT01951235) A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.